SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody aims to tame lupus by targeting troublemaking cells
Disease control Recruiting nowThis early-stage study tests a new drug called HB2198 in 30 adults with moderate to severe lupus, including kidney inflammation. The drug is designed to temporarily remove certain immune cells (B cells) that drive the disease. Participants receive two doses and are monitored for …
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Hinge Bio • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Experimental CAR-T therapy targets lupus and kidney disease in new trial
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-219C, which uses specially engineered immune cells (CAR-T cells) to target and destroy faulty B cells that drive autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusion a…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Engineered immune cells aim to tame autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
Could a Plant-Based compound help lupus patients control blood pressure?
Disease control Recruiting nowThis study tests whether a supplement called 2-HOBA can lower blood pressure and reduce immune system overactivity in women with lupus. About 42 participants will take either 2-HOBA or a placebo for 8 weeks, then switch after a break. The goal is to see if 2-HOBA can help manage …
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 10, 2026 13:29 UTC
-
Engineered immune cells take on lupus and kidney disease in new trial
Disease control Recruiting nowThis early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 03, 2026 12:05 UTC
-
Blood test could end guesswork in rheumatoid arthritis treatment
Diagnosis Recruiting nowThis study is testing a new blood test that may help doctors choose the most effective drug for each person with a rheumatic disease like rheumatoid arthritis or lupus. The test looks at how a patient's immune cells react to different medications before treatment starts. The goal…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Sponsor: University of Bonn • Aim: Diagnosis
Last updated Jun 15, 2026 19:05 UTC
-
New study aims to cut risky pills for seniors with arthritis
Knowledge-focused Recruiting nowThis study looks at whether a doctor's tool called MedSafer and patient brochures can help reduce the use of potentially unsafe medications in adults aged 60 and older with rheumatic diseases who take 5 or more regular drugs. Researchers will follow 100 participants for 18-20 mon…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:06 UTC